Research Applications Diverge From Corporate Activity as Diagnostics Draw 3.93 Research Records per Corporate Record While AI and Software Draw 0.11

InnoDexis has published its latest Innovation Intelligence Report covering applications and use cases, analyzing 3,581 research records and 4,840 corporate records mapped to 18 application sectors during the 1–29 September 2026 observation window. The report reveals that research and commerce aim at different users: research concentrates in clinical care, public health, climate and diagnostics, while corporate activity concentrates in AI and software, manufacturing, consumer and finance, and a corporate beneficiary is stated in only 39.9 percent of records. Research outnumbers corporate activity 3.9 to one in diagnostics.

Key Findings

Application sectors diverge. Research outnumbers corporate activity 3.93 to one in diagnostics, 3.86 in climate and environment and 3.78 in public health, while corporate activity outnumbers research about 9 to one in AI and software, 11 to one in consumer and lifestyle and 7 to one in telecom.

Readiness is highest where markets are thinnest. Research aimed at consumers is 23.0 percent High readiness, education 17.9 percent, public health 17.8 percent and finance 16.4 percent, while research aimed at electronics is 4.1 percent, telecom 4.8 percent, drug development 4.9 percent and manufacturing 5.8 percent.

Corporate momentum sits in physical-technology buyers. Energy carries 18.3 percent High momentum, drug development 17.0 percent, electronics 16.5 percent and AI and software 15.8 percent, against 6.6 percent in education, 8.8 percent in agriculture and 8.7 percent in diagnostics.

Corporate beneficiaries are mostly unstated. Beneficiaries are stated in 39.9 percent of corporate records, and where they are, financial institutions carry 23.3 percent High momentum, developers 20.5 percent and patients and clinicians 17.3 percent, against 5.4 percent for students and educators.

Research is multi-use but breadth does not buy readiness. Records average 2.06 application sectors and 401 name four or more, with industry transfer naming drug development in 799 records, clinical care in 727 and manufacturing in 701, while readiness is 14.8 percent at four sectors and 9.0 percent at five or more.

Strategic Insight and Trend Analysis

The defining structural finding is that value lies at the crossings between the streams. Institutional buyers, health systems, governments and regulators, are under-served, since diagnostics, public health and climate research outnumbers its corporate counterpart nearly four to one and these buyers procure slowly but at scale. Public-health research is 17.8 percent High readiness against 208 corporate records, and corporate scores in these sectors sit in the low fives. Named examples include Cornell’s front-of-package labelling and Oxford’s measures of 252 million children facing undernutrition or poverty.

Ready research meets a difficult market in consumer and education. Consumer research, from food and sleep to digital wellbeing, is the most ready at 23.0 percent, yet corporate momentum is 10.5 percent, and education research covering PISA analysis, digital-learning surveys and NEET risk is 17.9 percent ready against 6.6 percent corporate momentum. Finance is the one sector where research readiness, 16.4 percent, and corporate momentum, 15.3 percent, are both high.

Physical-technology buyers commit, and industry has to pull research forward. Energy, drugs and electronics buyers commit capital, sign trials and place orders, but research aimed at them is the least ready, 4.1 to 6.2 percent High, and the industry-transfer field points to pharma and manufacturing as the intended users. Corporate sector assignment is noisier than research assignment, so ratios are indicative.

Global and Industry Implications

For corporates and R&D teams, license research aimed at your industry and filter by the industry-transfer field, which names drug development in 799 records and manufacturing in 701, and use co-development where readiness is lowest. Named opportunities include manufacturing and construction AI from FernUniversität Hagen with STRABAG, timber construction at UC Berkeley and HPC partnerships with KIT. Industry should pull research forward, since readiness here is lowest.

For investors and capital allocators, back companies productising research-ready applications for institutional buyers, with diagnostics from Lund, Geneva and Liège research, public-health tools from Cornell, Oxford and Liverpool work and climate services from the New York State Mesonet, HZDR and VUB. Due diligence should identify the buyer and procurement route before the technology, and financial institutions, 23.3 percent High, are the most promising named beneficiaries. Startups should name a professional beneficiary.

For policymakers and national innovation bodies, public buyers are the natural customers for much ready research, so challenge-based procurement can create markets where research outnumbers products, in screening, prevention and climate monitoring, and in front-of-package labelling. Clinical and diagnostic applications still need approvals, with 660 marketing-approval and 212 device-pathway records named.

InnoDexis Statement

“Research aims at care, prevention and the planet; the market sells into software, consumers and finance — the value lies at the crossings, with institutional buyers for ready research and industrial pull for research that is not yet ready,” noted InnoDexis in its latest intelligence report.

Conclusion

Because sectors are multi-label keyword assignments, corporate assignment is noisier than research, readiness and momentum are analyst-assigned and one month supports no trend, the ratios are indicative. The signals to watch are whether a public tender appears for a research-ready application such as screening, prevention or climate data, whether a regulator mandates a research-proposed measure such as front-of-package labels, and whether companies name patients or clinicians as beneficiaries of research-derived products. The complete Applications & Use-Case Intelligence Report September 2026 is available to InnoDexis subscribers and enterprise clients.

About InnoDexis

InnoDexis is a real-time innovation intelligence platform connecting scientific discovery to commercial opportunity. Powered by InnoGraph, its proprietary innovation knowledge graph, the platform maps technologies across the entire lifecycle, from early-stage research (TRL 1) to market deployment (TRL 9), connecting researchers, institutions, startups, companies, products and emerging opportunities.

Covering 40+ specialised industry segments and 360 technology areas, InnoDexis delivers innovation tracking, research discovery, product and startup intelligence, investment insights, and AI-powered reports. Its mission is to bridge the gap between scientific discovery and real-world impact.

InnoDexis — From Lab to Market: Real-Time Innovation Intelligence.